Status:
COMPLETED
Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)
Lead Sponsor:
State University of New York at Buffalo
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Primary Progressive Multiple Sclerosis
Eligibility:
All Genders
18-65 years
Brief Summary
The goal of this non-interventional, observational study is to determine whether cortical pathology can be slowed down by use of ocrelizumab.
Detailed Description
To study the effect of ocrelizumab on cortical lesion accumulation in patients with primary-progressive multiple sclerosis participating in the ORATORIO: a post-hoc analysis of a double-blind, randomi...
Eligibility Criteria
Inclusion
- Patient participating in the ORATORIO study
- MRI scans available at baseline
- Presence of T2-weighted image (WI) (FLAIR, T2/PD), and 2D/3D T1-WI at baseline
Exclusion
- \- None
Key Trial Info
Start Date :
October 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 28 2024
Estimated Enrollment :
732 Patients enrolled
Trial Details
Trial ID
NCT05974839
Start Date
October 1 2023
End Date
February 28 2024
Last Update
September 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Buffalo Neuroimaging Analysis Center
Buffalo, New York, United States, 14203